Crossmark

Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion

Crossref DOI link: https://doi.org/10.1007/s00262-016-1864-z

Published Online: 2016-07-08

Published Print: 2016-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Wei

Erbe, Amy K.

Alderson, Kory A.

Phillips, Emily

Gallenberger, Mikayla

Gan, Jacek

Campana, Dario

Hank, Jacquelyn A.

Sondel, Paul M.
Funding

Funding for this research was provided by:

National Institutes of Health (CA166105)

National Institutes of Health (CA197078)

Hyundai Hope On Wheels

Midwest Athletes Against Childhood Cancer

The Stand Up To Cancer Foundation
License Information

Text and Data Mining valid from 2016-07-08

Version of Record valid from 2016-07-08
More Information

Article History

Received: 27 January 2016

Accepted: 29 June 2016

First Online: 8 July 2016

Compliance with ethical standards

:

: The authors have no financial conflicts of interest.

Document is current

Any future updates will be listed below